片頭痛（Migraine）：企業動向...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 9
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
2.3 Upcoming Related Reports 13
3 Market Outlook 14
3.1 Global Markets 14
3.1.1 Forecast 14
3.1.2 Drivers and Barriers – Global Issues 18
4 Current and Future Players 19
4.1 Overview 19
4.2 Trends in Corporate Strategy 22
4.3 Company Profiles 23
4.3.1 GlaxoSmithKline 23
4.3.2 AstraZeneca 26
4.3.3 Merck 28
4.3.4 Vernalis 30
4.3.5 Almirall 31
4.3.6 Pfizer 32
4.3.7 Zogenix 33
4.3.8 NuPathe 34
4.3.9 Allergan 36
4.3.10 RedHill Biopharma 37
4.3.11 OptiNose 38
4.3.12 CoLucid Pharmaceuticals 40
4.3.13 SUDA 41
4.3.14 Revance Therapeutics 42
4.3.15 NeurAxon 43
5 Appendix 45
5.1 Bibliography 45
5.2 Abbreviations 46
5.3 Methodology 47
5.4 Forecasting Methodology 47
5.4.1 Diagnosed Migraine Patients 47
5.4.2 Percent Drug-treated Patients 47
5.4.3 General Pricing Assumptions 48
5.4.4 Generic Erosion 49
5.5 Physicians and Specialists Included in this Study 49
5.6 Survey of Prescribing Physicians 50
5.7 About the Authors 51
5.7.1 Author 51
5.7.2 Reviewer 51
5.7.3 Global Head of Healthcare 52
5.8 About GlobalData 53
5.9 Disclaimer 53